| Literature DB >> 31550348 |
Jillian M Cotter1, Maribeth R Nicholson2, Larry K Kociolek3.
Abstract
Fecal microbiota transplantation (FMT) is efficacious for treatment of recurrent Clostridioides difficile infections (rCDIs). Pediatric experience with FMT for rCDIs is increasing, particularly at large centers. While retrospective studies suggest that FMT is generally safe in the short term, particularly in immunocompetent patients and with rigorous donor screening, additional large prospective studies are needed. This particularly includes those at high risk for infectious complications, such as immunocompromised hosts. Further, long-term implications of altering the intestinal microbiome with FMT are not well understood. The role of FMT in children, particularly in high-risk patients, will require continual reexamination with future availability of pediatric safety and efficacy data. This review summarizes key points for infectious diseases physicians to consider when evaluating a child for FMT.Entities:
Keywords: zzm321990 Clostridioides difficilezzm321990 ; zzm321990 Clostridium difficilezzm321990 ; fecal microbiota transplantation; safety; screening
Mesh:
Year: 2019 PMID: 31550348 PMCID: PMC7317149 DOI: 10.1093/jpids/piz062
Source DB: PubMed Journal: J Pediatric Infect Dis Soc ISSN: 2048-7193 Impact factor: 3.164